Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia.
作者信息
Zabriskie M S, Eide C A, Yan D, Vellore N A, Pomicter A D, Savage S L, Druker B J, Deininger M W, O'Hare T
机构信息
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
出版信息
Leukemia. 2016 Jun;30(6):1418-21. doi: 10.1038/leu.2015.318. Epub 2015 Nov 19.
Abstract
摘要
Zotero 插件